IP Library › Granted Patent US 12,247,214
Granted Patent B2
US 12,247,214 · App. 17/876,682 · Granted Mar 11, 2025

Vaccinia viral vectors encoding chimeric virus like particles

Inventors: Harriet Robinson (Palo Alto, CA); Arban Domi (Atlanta, GA); Michael Hellerstein (Marietta, GA); Farshad Guirakhoo (Atlanta, GA); Nathanael Paul McCurley (Decatur, GA)
Assignee: GeoVax, Inc.
C12N15/86A61K39/00117A61K2039/5158A61K2039/53A61K2039/55522C12N2710/24134C12N2710/24143Y02A50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,247,214
App. No.
17/876,682
Granted
Mar 11, 2025
Kind
B2
Abstract

The compositions and methods are described for generating an immune response to an antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens as a fusion product with a viral glycoprotein and matrix protein for generating a protective immune response to a subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat diseases.

Claims (35)

1. A method of inducing an immunological response in a human to a tumor associated antigen (TAA), the method comprising administering to the human a pharmaceutical composition comprising a recombinant modified vaccinia Ankara (MVA) viral vector in an amount sufficient to induce an immune response to the TAA, wherein the recombinant MVA viral vector comprises:

(i) a first nucleic acid sequence encoding a chimeric protein comprising (a) an extracellular fragment of the TAA, (b) a transmembrane domain of a glycoprotein (GP) of Marburg virus, and (c) an intracellular fragment of the TAA; and

(ii) a second nucleic acid sequence encoding a Marburg virus VP40 matrix protein;

wherein both the first nucleic acid sequence and the second nucleic acid sequence are under the control of one or more promoters compatible with poxvirus expression systems, and

wherein, upon expression, the chimeric protein and VP40 matrix protein are capable of assembling together to form virus-like particles (VLPs).

2. The method of claim 1 , wherein the chimeric protein comprises (a) an extracellular fragment of mucin-1 (MUC-1), (b) a transmembrane domain of a glycoprotein (GP) of Marburg virus, and (c) an intracellular fragment of MUC-1.

3. The method of claim 2 , wherein the extracellular fragment of MUC-1 is selected from the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 4, or an amino acid sequence at least 95% identical thereto.

4. The method of claim 1 , wherein the transmembrane domain of the GP of Marburg virus comprises the amino acid sequence of SEQ ID NO: 13, or an amino acid sequence at least 95% identical thereto.

5. The method of claim 2 , wherein the intracellular fragment of MUC-1 comprises amino acids 407-475 of SEQ ID NO: 6, or an amino acid sequence at least 95% identical thereto.

6. The method of claim 1 , wherein the first nucleic acid sequence encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence at least 95% identical thereto.

7. The method of claim 1 , wherein the first nucleic acid sequence encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 15.

8. The method of claim 1 , wherein the immune response is selected from a humoral immune response, a cellular immune response, production of neutralizing antibodies against the TAA, production of non-neutralizing antibodies against the TAA, or a combination thereof.

9. The method of claim 1 , wherein the pharmaceutical composition is administered simultaneously or sequentially.

10. The method of claim 1 , wherein the administration is repeated at least twice.

11. A method of inducing an immunological response in a human to mucin-1 (MUC-1), the method comprising administering a pharmaceutical composition comprising a recombinant modified vaccinia Ankara (MVA) viral vector to the human in an amount sufficient to induce an immune response to MUC-1, wherein the recombinant MVA viral vector comprises:

(i) a first nucleic acid sequence encoding a chimeric protein comprising (a) a MUC-1 antigenic peptide and (b) a transmembrane domain of a viral glycoprotein (GP) of Marburg virus, wherein the first nucleic acid sequence encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence at least 95% identical thereto, and

(ii) a second nucleic acid sequence encoding a viral Marburg virus VP40 matrix protein;

wherein the first nucleic acid sequence and second nucleic acid sequence are under the control of one or more promoters compatible with poxvirus expression systems, and

wherein, upon expression, the chimeric protein and VP40 matrix protein are capable of assembling together to form virus-like particles (VLPs).

12. The method of claim 11 , wherein the first nucleic acid sequence comprises a nucleic acid sequence selected from the nucleic acid sequence of SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 29, or a nucleic acid sequence at least 95% identical thereto.

13. The method of claim 11 , wherein the first nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 16.

14. The method of claim 11 , wherein the first nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 18.

15. The method of claim 11 , wherein the first nucleic acid sequence comprises the nucleic acid sequence of SEQ ID NO: 29.

16. The method of claim 11 , wherein the promoter is selected from Pm2H5, Psyn II, PmH5, or a combination thereof.

17. The method of claim 11 , wherein the first nucleic acid sequence is inserted between essential MVA genes I8R and G1L.

18. The method of claim 11 , wherein the second nucleic acid sequence is inserted in restructured and modified MVA deletion III region between MVA genes A50R and B1R.

19. A method of inducing an immunological response in a human to MUC-1, the method comprising administering a pharmaceutical composition comprising a recombinant modified vaccinia Ankara (MVA) viral vector to the human in an amount sufficient to induce an immune response, wherein the recombinant MVA viral vector comprises:

(i) a first nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 29, or a nucleic acid sequence at least 95% identical thereto, encoding a chimeric protein comprising the amino acid sequence of SEQ ID NO: 15, or an amino acid sequence at least 95% identical thereto, and

(ii) a second nucleic acid sequence encoding a Marburg virus VP40 matrix protein;

wherein the first nucleic acid sequence and second nucleic acid sequence are under the control of a PmH5 promoter;

wherein the first nucleic acid sequence is inserted between essential MVA genes 18R and G1L;

wherein the second nucleic acid sequence is inserted in restructured and modified MVA deletion III region between MVA genes A50R and BIR; and,

wherein upon expression, the chimeric protein and VP40 matrix protein are capable of assembling together to form virus-like particles (VLPs).

20. The method of claim 11 , wherein the first nucleic acid sequence encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 15.

21. The method of claim 19 , wherein the first nucleic acid sequence encodes an amino acid sequence comprising the amino acid sequence of SEQ ID NO: 15.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2025
From: ROBINSON, HARRIET; DOMI, ARBAN; HELLERSTEIN, MICHAEL
To: GEOVAX, INC.
Reel/Frame 070091/0978 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2025
From: ROBINSON, HARRIET; DOMI, ARBAN; HELLERSTEIN, MICHAEL; GUIRAKHOO, FARSHAD; MCCURLEY, NATHANAEL PAUL
To: GEOVAX, INC.
Reel/Frame 070091/0987 →
Continuity (5)
Continuation 16796350 · Feb 20, 2020
Continuation 16068527
Provisional Application 62301885 · Mar 1, 2016
Provisional Application 62276479 · Jan 8, 2016
Related Publication 20230040403A1 · Feb 9, 2023
References Cited (154)
US 4603112A · Paoletti et al. · 1986 [cited by applicant]
US 4722848A · Paoletti et al. · 1988 [cited by applicant]
US 4769330A · Paoletti et al. · 1988 [cited by applicant]
US 5445953A · Dorner et al. · 1995 [cited by applicant]
US 6103244A · Dorner et al. · 2000 [cited by applicant]
US 6440422B1 · Sutter et al. · 2002 [cited by applicant]
US 6696281B1 · Chambers et al. · 2004 [cited by applicant]
US 6998252B1 · Moss et al. · 2006 [cited by applicant]
US 7015024B1 · Moss et al. · 2006 [cited by applicant]
US 7045136B1 · Moss et al. · 2006 [cited by applicant]
US 7045313B1 · Moss et al. · 2006 [cited by applicant]
US 7795017B2 · Robinson et al. · 2010 [cited by applicant]
US 8288125B2 · Howley et al. · 2012 [cited by applicant]
US 8309326B2 · Howley et al. · 2012 [cited by applicant]
US 8414900B2 · Howley et al. · 2013 [cited by applicant]
US 8435543B2 · Howley et al. · 2013 [cited by applicant]
US 8623379B2 · Robinson et al. · 2014 [cited by applicant]
US 8859495B2 · Bamdad et al. · 2014 [cited by applicant]
US 8916172B2 · Moss et al. · 2014 [cited by applicant]
US 9133478B2 · Moss et al. · 2015 [cited by applicant]
US 9133480B2 · Moss et al. · 2015 [cited by applicant]
US 9295702B2 · Malarme et al. · 2016 [cited by applicant]
US 9453239B2 · Moss et al. · 2016 [cited by applicant]
US 9683020B2 · Compans et al. · 2017 [cited by applicant]
US 9879231B2 · Moss et al. · 2018 [cited by applicant]
US 10072058B2 · Wang et al. · 2018 [cited by applicant]
US 10258684B2 · Van Der Burg et al. · 2019 [cited by applicant]
US 20030215794A1 · Kawaoka et al. · 2003 [cited by applicant]
US 20040109876A1 · Yamamoto et al. · 2004 [cited by applicant]
US 20050036985A1 · Ensoli · 2005 [cited by applicant]
US 20050214256A1 · Megede et al. · 2005 [cited by applicant]
US 20060051759A1 · Salceda et al. · 2006 [cited by applicant]
US 20060088909A1 · Compans et al. · 2006 [cited by applicant]
US 20060099225A1 · Bavari et al. · 2006 [cited by applicant]
US 20060127413A1 · Sutter et al. · 2006 [cited by applicant]
US 20060216702A1 · Compans et al. · 2006 [cited by applicant]
US 20060286074A1 · Tang et al. · 2006 [cited by applicant]
US 20070160627A1 · Staib et al. · 2007 [cited by applicant]
US 20080193483A1 · Moss et al. · 2008 [cited by applicant]
US 20080199493A1 · Picker et al. · 2008 [cited by applicant]
US 20090069367A1 · Bamdad · 2009 [cited by applicant]
US 20090092628A1 · Mullins et al. · 2009 [cited by applicant]
US 20100047277A1 · Compans et al. · 2010 [cited by applicant]
US 20100196419A1 · Compans et al. · 2010 [cited by applicant]
US 20100330190A1 · Compans et al. · 2010 [cited by applicant]
US 20120052082A1 · Compans et al. · 2012 [cited by applicant]
US 20120219576A1 · Branco et al. · 2012 [cited by applicant]
US 20120263750A1 · Moss et al. · 2012 [cited by applicant]
US 20120289760A1 · Hill et al. · 2012 [cited by applicant]
US 20130101618A1 · Sullivan et al. · 2013 [cited by applicant]
US 20130280215A1 · Robinson · 2013 [cited by applicant]
US 20140050759A1 · Falkner et al. · 2014 [cited by applicant]
US 20140322265A1 · Chaplin et al. · 2014 [cited by applicant]
US 20150299290A1 · Boons et al. · 2015 [cited by applicant]
US 20160040135A1 · Moss et al. · 2016 [cited by applicant]
US 20160144011A1 · Collins et al. · 2016 [cited by applicant]
US 20160251406A1 · Schlom et al. · 2016 [cited by applicant]
US 20170304427A1 · Volkmann et al. · 2017 [cited by applicant]
US 20190290745A1 · Robinson et al. · 2019 [cited by applicant]
EP 0538496A1 · 1993 [cited by applicant]
EP 2402451A2 · 2012 [cited by applicant]
WO WO1994012617A1 · 1994 [cited by applicant]
WO WO1998008539A1 · 1998 [cited by applicant]
WO WO1999063062A1 · 1999 [cited by applicant]
WO WO2000003030A1 · 2000 [cited by applicant]
WO WO2002072754A2 · 2002 [cited by applicant]
WO WO2003078640A2 · 2003 [cited by applicant]
WO WO2003097845A1 · 2003 [cited by applicant]
WO WO2004048582A2 · 2004 [cited by applicant]
WO WO2005048957A2 · 2005 [cited by applicant]
WO WO2006026667A2 · 2006 [cited by applicant]
WO WO2006077161A1 · 2006 [cited by applicant]
WO WO2007012691A1 · 2007 [cited by applicant]
WO WO2007147528A1 · 2007 [cited by applicant]
WO WO2008142479A2 · 2008 [cited by applicant]
WO WO2010062757A1 · 2010 [cited by applicant]
WO WO2011047031A2 · 2011 [cited by applicant]
WO WO2011103417A2 · 2011 [cited by applicant]
WO WO2013059498A1 · 2013 [cited by applicant]
WO WO2014005958A1 · 2014 [cited by applicant]
WO WO2015009946A1 · 2015 [cited by applicant]
WO WO2015066715A1 · 2015 [cited by applicant]
WO WO20150175340A1 · 2015 [cited by applicant]
WO WO2016034678A2 · 2016 [cited by applicant]
WO WO2016068919A1 · 2016 [cited by applicant]
WO WO2016115116A1 · 2016 [cited by applicant]
WO WO2017120577A1 · 2017 [cited by applicant]
WO WO2017136419A1 · 2017 [cited by applicant]
WO WO2017143016A1 · 2017 [cited by applicant]
WO WO2017210181A1 · 2017 [cited by applicant]
WO WO2018195447A1 · 2018 [cited by applicant]
WO WO2019018501A1 · 2019 [cited by applicant]
WO WO2019040846A1 · 2019 [cited by applicant]
WO WO2019060356A1 · 2019 [cited by applicant]
WO WO2020247547A1 · 2020 [cited by applicant]
US, 2019/0117758, A1, U.S. Appl. No. 15/543,139, Robinson et al., Apr. 25, 2019. [cited by applicant]
U.S. Pat. No. 11,052,148, B2, U.S. Appl. No. 16/305,305, Guirakhoo et al., Jul. 6, 2021. [cited by applicant]
U.S. Pat. No. 11,278,607, B2, U.S. Appl. No. 16/068,527, Robinson et al., Mar. 22, 2022. [cited by applicant]
U.S. Pat. No. 11,098,086, A1, U.S. Appl. No. 16/077,215, Robinson, Harriet, Aug. 24, 2021. [cited by applicant]
US, 2020/0171141, A1, U.S. Appl. No. 16/631,489, Guirakhoo et al., Jun. 4, 2020. [cited by applicant]
U.S. Pat. No. 11,311,612, B2, U.S. Appl. No. 16/648,693, Guirakhoo et al., Apr. 26, 2022, [cited by applicant]
US, 2021/0220469, A1, U.S. Appl. No. 16/641,728, Guirakhoo, Farshad, Jul. 22, 2021. [cited by applicant]
U.S. Pat. No. 11,413,341, B2, U.S. Appl. No. 16/796,350, Robinson et al., Aug. 16, 2022. [cited by applicant]
US, 2021/0100891, A1, U.S. Appl. No. 17/000,768, Guirakhoo et al., Apr. 8, 2021. [cited by applicant]
US, 2022/0118082, A1, U.S. Appl. No. 17/368,761, Guirakhoo et al., Apr. 21, 2022. [cited by applicant]
US, 2022/0112248, A1, U.S. Appl. No. 17/409,574, Robinson, Harriet, Apr. 14, 2022. [cited by applicant]
US, 2022/0160853, A1, U.S. Appl. No. 17/542,100, Guirakhoo et al., May 26, 2022. [cited by applicant]
US, 2022/0152190, A1, U.S. Appl. No. 17/584,231, Robinson et al., May 19, 2022. [cited by applicant]
US, 2022/0313808, A1, U.S. Appl. No. 17/726,254, Guirakhoo et al., Oct. 6, 2022. [cited by applicant]
U.S. Appl. No. 17,888,131, Hauser et al., filed Aug. 15, 2022. [cited by applicant]
U.S. Appl. No. 17/950,989, Guirakhoo, Farshad, filed Sep. 22, 2022. [cited by applicant]
Kotsias, F. et al. International Review of Cell and Molecular Biology. 348:69-121(2019). [cited by applicant]
Larguier, L. Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-small Cell Lung Cancer. Business Wire. (Dec. 12, 2019). [cited by applicant]
Adu-Gyamfi, E. et al. The Ebola Virus Matrix Protein Penetrates into the Plasma Membrane. J. Infect. Dis., Jan. 7, 2014, vol. 210, No. 1, pp. 99-110. [cited by applicant]
Alharbi, N.K. et al. Enhancing cellular immunogenicity of MVA-vectored vaccines by utilizing the F11L endogenous promoter. Vaccine, 2015, 34(1), 49-55. [cited by applicant]
Anderson, R.J. et al. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine, 2007, 25, 24-34. [cited by applicant]
Antoine, G. et al. The complete genomic sequence of the modified vaccinia ankara strain: Comparison with other orthopoxviruses. Virology, 1998, 244, 365-396. [cited by applicant]
Brault, A.C. et al. A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model. Sci Rep., 2017, 7. [cited by applicant]
Brayman, M. et al. MUC1: a multifunctional cell surface component of reproductive tissue epithelia, Reprod. Biol Endocrinol., Jan. 7, 2004;2:4. doi: 10.1186/1477-7827-2-4. PMID: 14711375; PMCID: PMC320498. [cited by applicant]
Domi, A. et al. A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge. Sci Rep., 2018, 8, 864. [cited by applicant]
Earl, P.L. et al. Recombinant modified vaccinia virus ankara provides durable protection against disease caused by immunodeficiency virus as well as long term immunity to an orthopoxvirus in a non-human primate. Virolog… [cited by applicant]
European Search Report and Written Opinion for EP17736506 mailed on Jul. 22, 2019. [cited by applicant]
European Search Report and Written Opinion for EP17736506 mailed on May 27, 2020. [cited by applicant]
Fend, L. et al. Intravenous injection of MVA virus targets CD8+ lymphocytes to tumors to control tumor growth upon combinatorial treatment with a TLR9 agonist. Cancer Immunology Research, 2014, 2(12), 1163-1174. [cited by applicant]
GenBank Accession AFV312002, glycoprotein [Marburg Marburgvirus], Protein—NCBI; 3 pages; 2013. [cited by applicant]
Gendler, S.J. MUC1, the renaissance molecule. J. Mammary Gland Biol Neoplasia., 2001, 6 (3,: 339-353. [cited by applicant]
Goepfert, P.A. et al. National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network. Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1… [cited by applicant]
Goepfert, P.A. et al. National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network. Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara va… [cited by applicant]
Hessel, A. et al. MVA Vectors Expressing Conserved Influenza Proteins Protect Mice Against Lethal Challenge with H5N1, H942 and H7N1 Viruses. 2014, PLoS One, vol. 9, No. 2. [cited by applicant]
Holmes, K. et al. Assembly Pathway of Hepatitis B Core Vims-like Particles from Genetically 13 Fused Dimers. The Journal of Biological Chemistry, May 7, 2015. Vol. 290, No. 26, pp. 16238-16245. [cited by applicant]
International Search Report from PCT Patent Application No. PCT/US2017/012704, issued Apr. 13, 2017. [cited by applicant]
Lindén, S.K. et al. MUC1 limits Helicobacter pylori infection both by steric hindrance and by acting as a releasable decoy. PLoS Pathog, Oct. 2009, 5(10), e1000617. doi: 10.1371/journal.ppat.1000617. Epub Oct. 9, 2009. … [cited by applicant]
Lou Ming. A virus-life particle of HBV preS elicits robust immune responses—5th World Congress on hepatitis and liver diseases 2nd International Conference on Pancreatic Cancer and Liver Diseases. Journal of Liver, 2017… [cited by applicant]
Mackett, M. & Smith, G.L. Vaccinia virus expression vectors. J. Gen. Virology, 1986, 67, 2067-2082. [cited by applicant]
Malherbe, D.C. et al. Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection. Vaccines, 2020, 5(1), 78. [cited by applicant]
Manuel, E.R. et al. Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen A-specific immune responses. Virology, Elsevier, Amsterdam, NL, 2010, 403… [cited by applicant]
Mascola, J.R. et al. Novel vaccine technologies for the 21st century. Natures Review: Immunology, 2020, 20, 87-88. [cited by applicant]
Mittler, E. et al. The Cytoplasmic Domain of Marburg Virus GP Modulates Early Steps of Viral Infection. Journal of Virology, Jun. 15, 2011, vol. 85, No. 6, pp. 8188-8196. [cited by applicant]
Moss, B. et al. Reflections on the early development of poxvirus vectors. Vaccine, 2013, 31(39), 4220-4222. [cited by applicant]
Orubu, T. et al. Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA. PLoS One, 2012, 7(6), e40167 doi:10.1371/journal.pone.0040167. [cited by applicant]
Osborne, R.J. et al. An entomopoxvirus homologue of the vaccinia virus D13L-encoded rifampicin resistance protein. Journal of General Virology, 1996, 77, 839-846. [cited by applicant]
Pejawar-Gaddy, S. et al. Generation 1-16 of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papilloma virus virus-like particles. Cancer Immunology, 2010, 59(11), 1685-1696. [cited by applicant]
Rolland, M. et al. HIV-1 group M conserved element vaccine. PLo Pathogens, 2007, 3(11), 1551-1555. [cited by applicant]
Salvato, M.S. et al. A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge. Pathogens, 2019, 8:133. [cited by applicant]
Singh, P.K. & Hollingsworth, M.A. Cell surface-associated mucins in signal transduction. Trends Cell Biol. Sep. 2006;16(9):467-76. doi: 10.1016/j.tcb.2006.07.006. Epub Aug. 9, 2006. PMID: 16904320. [cited by applicant]
Staib, C. et al. Transient host range selection for genetic engineering of modified vaccinia virus ankara. Biotechniques, 2000, 28, 1137-1148. [cited by applicant]
Swenson, D.L. et al. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunology and Medical Microbiology., 2004, 40(1), pp. 27-31. [cited by applicant]
Thompson, M. et al. DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent… [cited by applicant]
Timm, A. et al. Genetic stability of recombinant MVA-BN. Vaccine, 2006, 24, 4618-4621. [cited by applicant]
Urata, S. & Yasuda, J. Cis- and cell-type-dependent trans-requirements for Lassa virus-like particle production. J. Gen. Virol., 2015, 96 Pt 7, 1626-1635. [cited by applicant]
Vietheer, P.T.K. et al. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies. Antiviral Therapy, 2007, 12, 477-487. [cited by applicant]
Wang, Z. et al. Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines. Vaccine, Feb. 10, 2010; 28(6): 1547. doi:10.1016/j… [cited by applicant]
Wyatt, L.S. et al. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine, 1996, 14(15), 1451-1458. [cited by applicant]
Xiaodan Cai et al. A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice. Antiviral Research, 2018, 149, 48-57. [cited by applicant]